{"id":"NCT00558025","sponsor":"Boehringer Ingelheim","briefTitle":"Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease","officialTitle":"A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-05","completion":null,"firstPosted":"2007-11-14","resultsPosted":"2009-11-20","lastUpdate":"2014-05-16"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Pramipexole Extended Release","otherNames":[]},{"type":"DRUG","name":"Pramipexole Immediate Release","otherNames":[]}],"arms":[{"label":"Pramipexole Extended Release (ER)","type":"EXPERIMENTAL"},{"label":"Pramipexole Immediate Release (IR)","type":"EXPERIMENTAL"}],"summary":"The objectives of this trial conducted in early Parkinson's disease (PD) patients are:\n\n* To assess if patients with early Parkinson's disease (PD) can be successfully switched (overnight switching) from Pramipexole (PPX) Immediate Release (IR) to Pramipexole Extended Release (ER). A successful switch at a specific visit is defined as no worsening of the Unified Parkinsons Disease Rating Scale (UPDRS) parts II+III score by more than 15% from baseline and no drug-related adverse events leading to withdrawal;\n* To establish if this successful switch can be obtained with or without dose-adaptation;\n* To provide information about the conversion ratio (mg:mg) from Pramipexole IR to Pramipexole ER.","primaryOutcome":{"measure":"Percentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS), Last Observation Carried Forward (LOCF)","timeFrame":"from baseline to week 9","effectByArm":[{"arm":"Pramipexole Extended Release (ER)","deltaMin":84.5,"sd":null},{"arm":"Pramipexole Immediate Release (IR)","deltaMin":94.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["France","Germany","Netherlands"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":104},"commonTop":[]}}